Form 4: Elevation Oncology Director R Michael Carruthers Acquires 35,000 Stock Options

R Michael Carruthers, a director at Elevation Oncology, acquired 35,000 stock options on June 13, 2024, according to a recent SEC filing.

Summary

• R Michael Carruthers, a director of Elevation Oncology, Inc. (ELEV), filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on June 13, 2024, where Carruthers acquired 35,000 stock options.
• These options have an exercise price of $3.35.
• The options vest 100% on the one-year anniversary of the grant date, contingent on Carruthers' continued service to the company.
• The expiration date for these options is June 12, 2034.
• Following the reported transaction, Carruthers directly owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider ownership can be a positive signal, this event alone doesn't strongly indicate a bullish or bearish outlook.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting of the options is contingent on the director's continued service to the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, such as directors and officers, trade in their company's securities. This filing provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates